目次

Table of Content

1. Introduction To Lung Cancer Antibody Drug Conjugates
1.1 Overview
1.2 Mechanism Of Antibody Drug Conjugates

2. Antibody Drug Conjugates As Lung Cancer Targeted Therapy
2.1 Applications Of Antibody Drug Conjugates In Lung Cancer
2.2 Advantages Of Antibody Drug Conjugates
2.3 Comparison Of Antibody Drug Conjugates With Traditional Therapies
2.4 Lung Cancer Antibody Drug Conjugates Combination Therapies

3. Generations Of Lung Cancer Antibody Drug Conjugates
3.1 Antibody Drug Conjugates - Evolution
3.2 Next Generation Antibody Drug Conjugates Prospects

4. Commercially Approved Lung Cancer Antibody Drug Conjugates By Brand Name, Company and Indication

5. Global Lung Cancer Antibody Drug Conjugates Market Outlook
5.1 Current Market Scenario
5.2 Global Lung Cancer Antibody Drug Conjugates Market Trends and Development
5.3 Future Growth Avenues

6. Global Lung Cancer Antibody Drug Conjugates Research and Market Trends by Region
6.1 US
6.2 China
6.3 Europe
6.4 Japan
6.5 South Korea

7. Approved Lung Cancer Antibody Drug Conjugates - Patent, Dosage and Price Analysis
7.1 Enhertu
7.1.1 Overview, Availability and Patent Insight
7.1.2 Pricing and Dosage Insight 7.2 Sacituzumab Tirumotecan
7.2.1 Overview, Availability and Patent Insight 7.3 Datroway
7.3.1 Overview and Availability Insight
7.3.2 Dosage and Price Analysis
7.4 Emrelis
7.4.1 Overview and Availability Insights
7.4.2 Pricing and Dosing Insight
7.5 Trastuzumab Rezetecan
7.5.1 Overview and Availability Insight

8. Global Lung Cancer Antibody Drug Conjugates Clinical Trials Overview
8.1 By Phase
8.2 By Indication
8.3 By Company
8.4 By Fast Track and Orphan Status
8.5 By Country

9. Global Lung Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase I/II
9.5 Phase II
9.6 Phase II/III
9.7 Phase III
9.8 Registration

10. Marketed Cancer Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase

11. Cancer Antibody Drug Conjugates Development Platforms By Company

12. Global lung Cancer Antibody Drug Conjugates Market Dynamics
12.1 Key Market Growth Drivers
12.2 Challenges For Market Growth

13. Competitive Landscape
13.1 ADC Therapeutics
13.2 AstraZeneca
13.3 Biocytogen
13.4 Biokin
13.5 Bristol Myers Squibb
13.6 Daiichi Sankyo
13.7 Duality Biologics
13.8 Gilead
13.9 Immunogen
13.10 Innovent Biologics
13.11 Kelun Biotech
13.12 LigaChem Biosciences
13.13 Merck
13.14 Pfizer
13.15 Roche

List of Figures & Tables
Figure 1-1: Antibody Drug Conjugates - General Working Mechanism
Figure 2-1: Advantages of Antibody Drug Conjugates
Figure 2-2: Lung Cancer - Antibody Drug Conjugate Combinations In Studies
Figure 3-1: Cancer Antibody Drug Conjugates - Opportunities For Next-Generation Development
Figure 5-1: Global - Lung Cancer Antibody Drug Conjugates Market (US$ Million), 2023-2025
Figure 5-2: IDeate-Lung02 Phase 3 (NCT06203210) Study - Initiation and Completion Year
Figure 5-3: SGNB6A-001 Phase 1 (NCT04389632) Study - Initiation and Completion Year
Figure 5-4: SGNB6A-002 Phase 3 (NCT06012435) Study - Initiation and Completion Year
Figure 5-5: MK-2870-004 Phase 3 (NCT06074588) Study - Initiation and Completion Year
Figure 5-6: SHR-4849-101 Phase 1 (NCT06443489) Study - Initiation and Completion Year
Figure 5-7: Global - Lung Cancer Antibody Drug Conjugate Market Forecast (US$ Million), 2026 - 2030
Figure 7-1: Enhertu - Cost Of Supply In US and Europe (US$), September’2025
Figure 7-2: Datroway - Cost Of 100 mg Supply In US and Europe (US$), September’2025
Figure 7-3: Emrelis - Cost Per Supply (US$), September’2025
Figure 8-1: Global - Lung Cancer Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2030
Figure 8-2: Global- Cancer Antibody Drug Conjugate In Clinical Trials By Indication, 2025 Till 2030
Figure 8-3: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Company, 2025 Till 2030
Figure 8-4: Global - Cancer Antibody Drug Conjugate In Clinical Trials By Fast Track and Orphan Status, 2025 Till 2030
Figure 8-5: Global - Cancer Antibody Drug Conjugate In Clinical Pipeline By Country, 2025 Till 2030
Figure 11-1: Proprietary ADC Technology - Seagen
Figure 11-2: ALE.P02 and ALE.P03 - Alentis Therapeutics
Figure 11-3: TRAAC - Tallac Therapeutics
Figure 11-4: ATAC - Heidelberg Pharma
Figure 11-5: Tub-tagandreg; and P5 - Tubulis
Table 2-1: Lung Cancer - Antibody Drug Conjugates vs. Traditional Therapies
Table 2-2: Lung Cancer - Ongoing Antibody Drug Conjugate Combination Clinical Trials
Table 3-1: Lung Cancer - Approved Second Generation Antibody Drug Conjugates
Table 3-2: Lung Cancer - Approved Third Generation Antibody Drug Conjugates
Table 3-3: Lung Cancer - Approved Fourth Generation Antibody Drug Conjugates
Table 3-4: Lung Cancer - Summary Of Antibody-Drug Conjugate Generations
Table 4-1: Lung Cancer - Approved Antibody Drug Conjugates, September’2025
Table 6-1: US - Approved Lung Cancer Antibody Drug Conjugates, September’2025
Table 6-2: China - Approved Lung Cancer Antibody Drug Conjugates, September’2025
Table 6-3: EU - Approved Cancer Antibody Drug Conjugates, September’2025
Table 6-4: Japan - Approved Cancer Antibody Drug Conjugates, September’2025
Table 7-1: Datroway - Premedication and Concomitant Medications
Table 7-2: Datroway - Recommended Dosage Reductions For Adverse Reactions
Table 7-3: Emrelis: Recommended Dose Reductions